What is the recommended dosing schedule for a 26‑week oral BPaL regimen (bedaquiline, pretomanid, linezolid) for drug‑resistant tuberculosis?

BPaL Regimen Dosing for Drug-Resistant Tuberculosis

The recommended 26-week oral BPaL regimen consists of bedaquiline (with two dosing options), pretomanid 200 mg once daily, and linezolid 600 mg once daily, all administered with food under directly observed therapy. 1, 2

Core Regimen Components

Pretomanid

• 200 mg orally once daily for 26 weeks with food 2
• Administer whole with water, or crush/suspend in water for patients with swallowing difficulties 2

Bedaquiline – Two Acceptable Dosing Options

Option 1 (Traditional dosing):

• 400 mg once daily for 2 weeks, then
• 200 mg three times per week (with ≥48 hours between doses) for 24 weeks
• Total duration: 26 weeks 1, 2

Option 2 (Simplified daily dosing):

• 200 mg once daily for 8 weeks, then
• 100 mg once daily for 18 weeks
• Total duration: 26 weeks 1, 2

Linezolid – Preferred Dosing

The preferred linezolid dose is 600 mg once daily for the full 26 weeks. 1, 2

• This dosing is based on the ZeNix randomized trial, which demonstrated that 600 mg daily yields higher treatment success, lower failure/recurrence rates, and fewer adverse events compared to 1200 mg daily 1, 3
• An alternative 1200 mg daily regimen exists but carries substantially higher toxicity (38% peripheral neuropathy, 22% myelosuppression) versus 600 mg (24% and 2%, respectively) 3

Toxicity Management for Linezolid

If myelosuppression, peripheral neuropathy, or optic neuropathy occurs, reduce linezolid to 300 mg once daily or interrupt dosing. 2

• The 300 mg dose reduction maintains efficacy while reducing toxicity, particularly peripheral neuropathy 1, 4
• Recent evidence from India shows structured dose reduction (600 mg for 9-13 weeks, then 300 mg for remainder) achieves comparable cure rates (93-94%) with significantly less peripheral neuropathy (13-19% vs 30%) 4
• Do not make up missed linezolid doses that were interrupted due to adverse reactions 2

Treatment Duration and Completion Window

• All prescribed doses should be completed within 26 weeks, with an overall window of 7 months to accommodate interruptions 1
• Dosing can be extended beyond 26 weeks if necessary for safety reasons 2
• Missed doses of the combination (for safety reasons) can be made up at the end of treatment 2

Critical Administration Requirements

• All three drugs must be administered together with food under directly observed therapy (DOT) 2
• The regimen must not be used with drugs other than these three specific agents 2

Pre-Treatment Assessments

Before initiating BPaL, obtain:

• Liver function tests (ALT, AST, alkaline phosphatase, bilirubin) and assess for hepatic symptoms 2
• Complete blood count 2
• Serum potassium, calcium, and magnesium (correct if abnormal) 2
• Baseline ECG 2

Important Caveats

• BPaL is indicated only for highly resistant TB (resistant to isoniazid, rifamycins, fluoroquinolones, and injectable agents) or treatment-intolerant/non-responsive MDR-TB 2
• Not indicated for drug-sensitive TB, latent TB, extrapulmonary TB, or patients with known resistance to any BPaL component 2
• Safety not established in pregnancy, breastfeeding, or patients under 18 years 2
• Pretomanid caused testicular atrophy and impaired fertility in male rats; counsel patients accordingly 2